1
|
Ashraf-Uz-Zaman M, Shahi S, Akwii R, Sajib MS, Farshbaf MJ, Kallem RR, Putnam W, Wang W, Zhang R, Alvina K, Trippier PC, Mikelis CM, German NA. Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem 2021; 209:112866. [PMID: 33039722 PMCID: PMC7744370 DOI: 10.1016/j.ejmech.2020.112866] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 09/13/2020] [Accepted: 09/16/2020] [Indexed: 12/13/2022]
Abstract
Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data using in silico model. Overall, we envision that these compounds can be further developed for the potential treatment of metastatic breast cancer.
Collapse
Affiliation(s)
- Md Ashraf-Uz-Zaman
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
| | - Sadisna Shahi
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
| | - Racheal Akwii
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
| | - Md Sanaullah Sajib
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
| | | | - Raja Reddy Kallem
- Clinical Pharmacology & Experimental Therapeutics Center, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - William Putnam
- Clinical Pharmacology & Experimental Therapeutics Center, Texas Tech University Health Sciences Center, Dallas, TX, USA
| | - Wei Wang
- College of Pharmacy, University of Houston, Houston, TX, USA
| | - Ruiwen Zhang
- College of Pharmacy, University of Houston, Houston, TX, USA
| | - Karina Alvina
- Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Department of Biological Sciences, Texas Tech University, Lubbock, TX, USA; Department of Neuroscience, University of Florida, Gainesville, FL, USA
| | - Paul C Trippier
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA; Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA
| | - Constantinos M Mikelis
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA
| | - Nadezhda A German
- Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA; Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
| |
Collapse
|
2
|
Ashraf-Uz-Zaman M, Sajib MS, Cucullo L, Mikelis CM, German NA. Analogs of penfluridol as chemotherapeutic agents with reduced central nervous system activity. Bioorg Med Chem Lett 2018; 28:3652-3657. [PMID: 30389290 DOI: 10.1016/j.bmcl.2018.10.036] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Revised: 10/21/2018] [Accepted: 10/23/2018] [Indexed: 11/30/2022]
Abstract
Several recent reports have highlighted the feasibility of the use of penfluridol, a well-known antipsychotic agent, as a chemotherapeutic agent. In vivo experiments have confirmed the cytotoxic activity of penfluridol in triple-negative breast cancer model, lung cancer model, and further studies have been proposed to assess its anticancer activity and viability for the treatment of glioblastomas. However, penfluridol anticancer activity was observed at a dosage significantly higher than that administered in antipsychotic therapy, thus raising the concern for the potential onset of CNS side effects in patients undergoing intensive pharmacological treatment. In this study, we evaluate the potential CNS toxicity of penfluridol side by side with a set of analogs.
Collapse
Affiliation(s)
- Md Ashraf-Uz-Zaman
- Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106, United States
| | - Md Sanaullah Sajib
- Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106, United States
| | - Luca Cucullo
- Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106, United States
| | - Constantinos M Mikelis
- Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106, United States
| | - Nadezhda A German
- Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, TX 79106, United States.
| |
Collapse
|
3
|
Kumar V, Yarravarapu N, Lapinsky DJ, Perley D, Felts B, Tomlinson MJ, Vaughan RA, Henry LK, Lever JR, Newman AH. Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram. J Med Chem 2015; 58:5609-19. [PMID: 26153715 PMCID: PMC4515784 DOI: 10.1021/acs.jmedchem.5b00682] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
![]()
Three photoaffinity ligands (PALs)
for the human serotonin transporter
(hSERT) were synthesized based on the selective serotonin reuptake
inhibitor (SSRI), (S)-citalopram (1).
The classic 4-azido-3-iodo-phenyl group was appended to either the
C-1 or C-5 position of the parent molecule, with variable-length linkers,
to generate ligands 15, 22, and 26. These ligands retained high to moderate affinity binding (Ki = 24–227 nM) for hSERT, as assessed
by [3H]5-HT transport inhibition. When tested against Ser438Thr
hSERT, all three PALs showed dramatic rightward shifts in inhibitory
potency, with Ki values ranging from 3.8
to 9.9 μM, consistent with the role of Ser438 as a key residue
for high-affinity binding of many SSRIs, including (S)-citalopram. Photoactivation studies demonstrated irreversible adduction
to hSERT by all ligands, but the reduced (S)-citalopram
inhibition of labeling by [125I]15 compared
to that by [125I]22 and [125I]26 suggests differences in binding mode(s). These radioligands
will be useful for characterizing the drug–protein binding
interactions for (S)-citalopram at hSERT.
Collapse
Affiliation(s)
- Vivek Kumar
- †Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States
| | - Nageswari Yarravarapu
- ‡Division of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States
| | - David J Lapinsky
- ‡Division of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, United States
| | - Danielle Perley
- §Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, United States
| | - Bruce Felts
- §Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, United States
| | - Michael J Tomlinson
- §Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, United States
| | - Roxanne A Vaughan
- §Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, United States
| | - L Keith Henry
- §Department of Basic Sciences, University of North Dakota School of Medicine and Health Sciences, Grand Forks, North Dakota 58202, United States
| | - John R Lever
- ∥Department of Radiology, University of Missouri, One Hospital Drive, Columbia, Missouri 65212, United States.,⊥Harry S. Truman Memorial Veterans' Hospital, 800 Hospital Drive, Columbia, Missouri 65201, United States
| | - Amy Hauck Newman
- †Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States
| |
Collapse
|
4
|
Bao H, Wang D, Wang X, Cheng C, Li Y, Hu Y. Hydrogenation of (N,N-disubstituted aminomethyl)nitrobenzenes to (N,N-disubstituted aminomethyl)anilines catalyzed by palladium–nickel bimetallic nanoparticles. RSC Adv 2015. [DOI: 10.1039/c5ra07208e] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A Pd–Ni bimetallic nanoparticles catalyzed hydrogenation of (N,N-disubstituted aminomethyl)nitrobenzenes to (N,N-disubstituted aminomethyl)anilines was achieved chemoselectively.
Collapse
Affiliation(s)
- Hailin Bao
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P. R. China
| | - Dingsheng Wang
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P. R. China
| | - Xinyan Wang
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P. R. China
| | - Chuanjie Cheng
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P. R. China
| | - Yadong Li
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P. R. China
| | - Yuefei Hu
- Department of Chemistry
- Tsinghua University
- Beijing 100084
- P. R. China
| |
Collapse
|
5
|
Lapinsky DJ, Velagaleti R, Yarravarapu N, Liu Y, Huang Y, Surratt CK, Lever JR, Foster JD, Acharya R, Vaughan RA, Deutsch HM. Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling. Bioorg Med Chem 2011; 19:504-12. [PMID: 21129986 PMCID: PMC3023924 DOI: 10.1016/j.bmc.2010.11.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 10/25/2010] [Accepted: 11/01/2010] [Indexed: 11/20/2022]
Abstract
In contrast to tropane-based compounds such as benztropine and cocaine, non-tropane-based photoaffinity ligands for the dopamine transporter (DAT) are relatively unexplored. Towards addressing this knowledge gap, ligands were synthesized in which the piperidine nitrogen of 3- and 4-iodomethylphenidate was substituted with a benzyl group bearing a photoreactive azide. Analog (±)-3a demonstrated modest DAT affinity and a radioiodinated version was shown to bind covalently to rat striatal DAT and hDAT expressed in cultured cells. Co-incubation of (±)-3a with nonradioactive d-(+)-methylphenidate or (-)-2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane (β-CFT, WIN-35,428, a cocaine analog) blocked DAT labeling. Compound (±)-3a represents the first successful example of a DAT photoaffinity ligand based on the methylphenidate scaffold. Such ligands are expected to assist in mapping non-tropane ligand-binding pockets within plasma membrane monoamine transporters.
Collapse
Affiliation(s)
- David J Lapinsky
- Division of Pharmaceutical Sciences, Duquesne University Mylan School of Pharmacy, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Lapinsky DJ, Aggarwal S, Huang Y, Surratt CK, Lever JR, Foster JD, Vaughan RA. A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem 2009; 17:3770-4. [PMID: 19442525 PMCID: PMC2696686 DOI: 10.1016/j.bmc.2009.04.057] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2009] [Revised: 04/22/2009] [Accepted: 04/24/2009] [Indexed: 10/20/2022]
Abstract
Non-tropane-based photoaffinity ligands for the dopamine transporter (DAT) are relatively unexplored in contrast to tropane-based compounds such as cocaine. In order to fill this knowledge gap, a ligand was synthesized in which the aromatic ring of pyrovalerone was substituted with a photoreactive azido group. The analog 1-(4-azido-3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one demonstrated appreciable binding affinity for the DAT (K(i)=78+/-18 nM), suggesting the potential utility of a radioiodinated version in structure-function studies of this protein.
Collapse
Affiliation(s)
- David J Lapinsky
- Division of Pharmaceutical Sciences, Duquesne University Mylan School of Pharmacy, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
| | | | | | | | | | | | | |
Collapse
|
7
|
Cheng C, Wang X, Xing L, Liu B, Zhu R, Hu Y. An Efficient and Practical Method for Highly Chemoselective Hydrogenation of Nitrobenzylamines to Aminobenzylamine Hydrochlorides. Adv Synth Catal 2007. [DOI: 10.1002/adsc.200600521] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|